|
| | SB0101 Enrolled | | LRB103 25077 BMS 51412 b |
|
|
1 | | AN ACT concerning regulation.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Illinois Insurance Code is amended by |
5 | | changing Section 356z.25 as follows: |
6 | | (215 ILCS 5/356z.25) |
7 | | Sec. 356z.25. Coverage for treatment of pediatric |
8 | | autoimmune neuropsychiatric disorders associated with |
9 | | streptococcal infections and pediatric acute onset |
10 | | neuropsychiatric syndrome. A group or individual policy of |
11 | | accident and health insurance or managed care plan that is |
12 | | amended, delivered, issued, or renewed after July 18, 2017 |
13 | | (the effective date of Public Act 100-24) shall provide |
14 | | coverage for treatment of pediatric autoimmune |
15 | | neuropsychiatric disorders associated with streptococcal |
16 | | infections and pediatric acute-onset neuropsychiatric |
17 | | syndrome, including, but not limited to, the use of |
18 | | intravenous immunoglobulin therapy. |
19 | | No group or individual policy of accident and health |
20 | | insurance or managed care plan shall deny or delay coverage |
21 | | for medically necessary treatment under this Section solely |
22 | | because the insured, enrollee, or beneficiary previously |
23 | | received any treatment, including the same or similar |
|
| | SB0101 Enrolled | - 2 - | LRB103 25077 BMS 51412 b |
|
|
1 | | treatment, for pediatric autoimmune neuropsychiatric disorders |
2 | | associated with streptococcal infections or pediatric acute |
3 | | onset neuropsychiatric syndrome, or because the insured, |
4 | | enrollee, or beneficiary has been diagnosed with or receives |
5 | | treatment for an otherwise diagnosed condition. |
6 | | For the purposes of this Section, coverage of pediatric |
7 | | autoimmune neuropsychiatric disorders associated with |
8 | | streptococcal infections and pediatric acute onset |
9 | | neuropsychiatric syndrome shall adhere to the treatment |
10 | | recommendations developed by a medical professional consortium |
11 | | convened for the purposes of researching, identifying, and |
12 | | publishing best practice standards for diagnosis and treatment |
13 | | of such disorders or syndrome that are accessible for medical |
14 | | professionals and are based on evidence of positive patient |
15 | | outcomes. Coverage for any form of medically necessary |
16 | | treatment shall not be limited over a lifetime of an insured, |
17 | | enrollee, or beneficiary, unless the patient is no longer |
18 | | benefiting from the treatment, or by policy period. Nothing in |
19 | | this Section prevents insurers from requesting treatment notes |
20 | | and anticipated duration of treatment and outcomes. |
21 | | For billing and diagnosis purposes, pediatric autoimmune |
22 | | neuropsychiatric disorders associated with streptococcal |
23 | | infections and pediatric acute onset neuropsychiatric syndrome |
24 | | shall be coded as autoimmune encephalitis until the American |
25 | | Medical Association and the Centers for Medicare and Medicaid |
26 | | Services create and assign a specific code for pediatric |
|
| | SB0101 Enrolled | - 3 - | LRB103 25077 BMS 51412 b |
|
|
1 | | autoimmune neuropsychiatric disorders associated with |
2 | | streptococcal infections and pediatric acute onset |
3 | | neuropsychiatric syndrome. Thereafter, pediatric autoimmune |
4 | | neuropsychiatric disorders associated with streptococcal |
5 | | infections and pediatric acute onset neuropsychiatric syndrome |
6 | | may be coded as autoimmune encephalitis, pediatric autoimmune |
7 | | neuropsychiatric disorders associated with streptococcal |
8 | | infections, or pediatric acute onset neuropsychiatric |
9 | | syndrome. |
10 | | If, at any time, the Secretary of the United States |
11 | | Department of Health and Human Services, or its successor |
12 | | agency, promulgates rules or regulations to be published in |
13 | | the Federal Register or publishes a comment in the Federal |
14 | | Register or issues an opinion, guidance, or other action that |
15 | | would require the State, pursuant to any provision of the |
16 | | Patient Protection and Affordable Care Act (Public Law |
17 | | 111-148), including, but not limited to, 42 U.S.C. |
18 | | 18031(d)(3)(B) or any successor provision, to defray the cost |
19 | | of any coverage for pediatric autoimmune neuropsychiatric |
20 | | disorders associated with streptococcal infections and |
21 | | pediatric acute onset neuropsychiatric syndrome outlined in |
22 | | this Section, then the requirement that an insurer cover |
23 | | pediatric autoimmune neuropsychiatric disorders associated |
24 | | with streptococcal infections and pediatric acute onset |
25 | | neuropsychiatric syndrome is inoperative other than any such |
26 | | coverage authorized under Section 1902 of the Social Security |
|
| | SB0101 Enrolled | - 4 - | LRB103 25077 BMS 51412 b |
|
|
1 | | Act, 42 U.S.C. 1396a, and the State shall not assume any |
2 | | obligation for the cost of coverage for pediatric autoimmune |
3 | | neuropsychiatric disorders associated with streptococcal |
4 | | infections and pediatric acute onset neuropsychiatric |
5 | | syndrome.
|
6 | | (Source: P.A. 100-24, eff. 7-18-17; 100-863, eff. 8-14-18; |
7 | | 101-488, eff. 8-23-19.)
|
8 | | Section 99. Effective date. This Act takes effect upon |
9 | | becoming law. |